PRESS RELEASE · Safety Studies
Release date
TFA Reports Completion of Preliminary 14-Day TF-15 Rat Study
The preliminary TF-15 study report is complete, informing dose selection and formal study design
- The company has received a signed report for the preliminary 14-day study in 24 female rats.
- Further research covers target-animal safety, toxicology, residues, and formulation to support TFA-01 development.
TFA Therapeutics, Inc. (OTCQB: RAJAF) provided an update on its preliminary safety research. The company completed a preliminary 14-day repeat-dose study of TF-15 in 24 female rats. The summary report was signed on July 2, 2026, and will inform dose selection and the design of subsequent studies.
The study generated early observations on dosing and tolerability. Further data are needed to relate the TF-15 used in this study to purified Antcin A, TFA-01 study materials, and the final formulation, accounting for composition, batches, and preparation methods.
TFA is advancing research on target-animal safety, toxicology, residues, and nanoformulations through contracted research teams. The work will support injectable formulation development and build the drug candidate's safety and quality dataset.
The company will integrate study reports, pharmacokinetic data, and formulation quality data to support product design and regulatory submission preparation. Study progress and conclusions will be reported once the data are confirmed.
The 14-day TF-15 rat study is preliminary and exploratory. It is neither a GLP regulatory toxicology study nor a long-term safety study, and it does not directly establish safety in dogs or the safety of purified Antcin A or the final product.
About TFA
TFA Therapeutics, Inc. (OTCQB: RAJAF) is developing TFA-01, an Antcin A-based drug candidate, with canine osteoarthritis as its initial target indication. The program includes source material and formulation development, as well as safety and efficacy evaluation.
Forward-looking statements: The development plans described in this release may change in response to study results, regulatory requirements, and funding arrangements. Actual progress and outcomes may differ from current expectations.